Efalizumab: Anti-CD11a monoclonal antibody - Genentech/Xoma, HU 1124, hu1124, Xanelim

Drugs in R and D

Volumn 3, Issue 1, 2002, Pages 40-43

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; HU 1124; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN;

ARTICLE; BIOEQUIVALENCE; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FEVER; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HEADACHE; HUMAN; KIDNEY TRANSPLANTATION; NAUSEA; PAIN; PRIORITY JOURNAL; PSORIASIS VULGARIS; RHINITIS; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; ANIMAL; PSORIASIS; REVIEW; SKIN DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; SKIN DISEASES;

EID: 0036359550     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203010-00009     Document Type: Article

References (7)

1. Papp KA, Bissonette R, Goldwater R, Pehr K, Ouellet J-P, et al. The treatment of moderate to severe psoriasis with hu 1124: a new monoclonal antibody. British Journal of Dermatology. 141: 980, Nov 1999. Canada. [English]
2. XOMA Ltd. Anti-CD11a monoclonal antibody Xanelim shows positive results in 12-week dosing and retreatment studies. Media Release.: [3 pages], 5 Mar 2001. Available from: URL: http://www.xoma.com. USA. [English]
3. Leonardi CL, Gottlieb A, Miller B, Tashjian D, Pariser D, et al. Anti-CD11a: results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis.59th Annual Meeting American Academy of Dermatology. : 506 (plus poster), 2 Mar 2001. USA. [English]
4. Genentech Inc, XOMA Ltd. Xanelim shows initial positive results in second pivotal phase III study. Media Release.: [5 pages], 30 Jul 2001. Available from: URL: http://www.gene.com. USA. [English]
5. Vincenti F, Mendez R, Rajagopalan PR, Wilkinson A, Butt K, et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. American Journal of Transplantation. 1 (Suppl 1): 276, 2001. USA. [English]
6. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, et al. Effects of administrations of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. Journal of the American Academy of Dermatology. 42: 428-435, Mar 2000. USA. [English]
7. Gottlieb AB, Krueger J, Abdulghani A, et al. Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11A monoclonal antibody (HU1124): results of a multicenter, multiple ascending dose study. Arthritis and Rheumatism. 42 (Suppl): 373, Sep 1999. USA. [English] F